

Supporting Information for

**Ag(I)-Catalyzed Tandem [6 + 3] Annulation/Isomerization of
Isocyanoacetates with Fulvenes: An Expedient Approach to Fused
Dihydropyridines**

Zhao-Lin He, Chun-Jiang Wang*

E-mail: cjwang@whu.edu.cn

Table of Contents


I.	General Remarks.....	S2
II.	General Procedure for Ag(I)-Catalyzed [6 + 3] Cycloaddition/Isomerization of Isocyanoacetates 1 with Fulvenes 2	S2-S10
III.	Preliminary Results for Catalytic asymmetric [6 + 3] Cycloaddition/Isomer-ization of Isocyanoacetate 1a with Fulvene 2a	S11
IV.	References.....	S11
V.	¹ H NMR and ¹³ C NMR Spectra.....	S12-S51
VI.	HPLC Chromatograms.....	S52-S53

I. General Remarks

¹H NMR spectra were recorded on a VARIAN Mercury 300 MHz or Bruker 400 MHz spectrometer in CDCl₃. Chemical shifts are reported in ppm with the internal TMS signal at 0.0 ppm as a standard. The data are reported as (s = single, d = double, t = triple, q = quarte, m = multiple or unresolved, brs = broad single, coupling constant(s) in Hz, integration). ¹³C NMR spectra were recorded on a VARIAN Mercury 75 MHz or Bruker 100 MHz spectrometer in CDCl₃. Chemical shifts are reported in ppm with the internal chloroform signal at 77.0 ppm as a standard. Commercially obtained reagents were used without further purification. All reactions were monitored by TLC with silica gel-coated plates. Enantiomeric ratios were determined by HPLC, using a chiralpak AS-H column with hexane and *i*-PrOH as solvents. Fulvenes¹ and isocyanoacetates² were prepared according to the literature procedure. Chiral ligand TF-BiphamPhos was prepared according our previous procedure.³

II. General Procedure for Ag(I)-Catalyzed [6 + 3] Cycloaddition/Isomerization of Isocyanoacetates **1** with Fulvenes **2**


Under argon atmosphere, AgOAc (2.0 mg, 0.012 mmol) and PPh₃ (6.9 mg, 0.026 mmol) were dissolved in 2 mL DCM, and stirred at room temperature for about 30 min. Then, isocyanoacetate **2** (0.4 mmol), Et₃N (0.06 mmol) and fulvene **1** (0.6 mmol) was added sequentially. Once starting material was consumed (monitored by TLC), then the organic solvent was removed and the residue was purified by column chromatography to give the product.



Methyl 4,4-dimethyl-3,4-dihydro-2H-cyclopenta[c]pyridine-3-carboxylate


The title compound was prepared according to the general procedure as described above in 90% yield. ¹H NMR (CDCl₃, TMS, 300 MHz) δ 7.29 (d, *J* = 5.7 Hz, 1H), 6.28 (m, 2H), 6.08 (s, 1H), 5.82 (br, 1H), 4.13 (s, 1H), 3.85 (s, 3H), 1.56 (s, 3H), 1.01 (s, 3H); ¹³C NMR (CDCl₃, TMS, 75 MHz) δ 171.1, 139.4, 135.1, 124.2, 116.2, 114.7, 65.6, 52.4, 36.8, 25.1, 24.0; HRMS Calcd.

For $C_{12}H_{15}NO_2^+$: 205.1103, found: 205.1104.




Benzyl 4,4-dimethyl-3,4-dihydro-2H-cyclopenta[c]pyridine-3-carboxylate

The title compound was prepared according to the general procedure as described above in 95% yield. 1H NMR ($CDCl_3$, TMS, 300 MHz) δ 7.40-7.33 (m, 5H), 7.28-7.25 (m, 1H), 6.26 (s, 2H), 6.05 (s, 1H), 5.81 (br, 1H), 5.32 (d, $J = 12.0$ Hz, 1H), 5.22 (d, $J = 12.0$ Hz, 1H), 4.14 (s, 1H), 1.53 (s, 3H), 0.97 (s, 3H); ^{13}C NMR ($CDCl_3$, TMS, 75 MHz) δ 172.0, 139.5, 135.0, 124.0, 117.5, 116.1, 114.6, 65.6, 52.3, 36.7, 25.2, 24.0; HRMS Calcd. For $C_{18}H_{19}NO_2^+$: 281.1416, found: 281.1414.



Benzyl 4,4-diethyl-3,4-dihydro-2H-cyclopenta[c]pyridine-3-carboxylate


The title compound was prepared according to the general procedure as described above in 78% yield. 1H NMR ($CDCl_3$, TMS, 300 MHz) δ 7.39 (m, 5H), 7.20 (d, $J = 6.0$ Hz, 1H), 6.29-6.28 (m, 2H), 5.97 (s, 1H), 5.70 (br, 1H), 4.50 (s, 1H), 2.09-2.02 (m, 1H), 1.75-1.57 (m, 3H), 1.07 (t, $J = 7.5$ Hz, 3H), 0.64 (t, $J = 7.5$ Hz, 3H); ^{13}C NMR ($CDCl_3$, TMS, 75 MHz) δ 170.7, 138.9, 134.8, 133.7, 133.5, 128.6, 128.3, 123.7, 118.8, 117.4, 116.3, 67.4, 61.3, 44.7, 27.7, 26.0, 8.8, 8.0; HRMS Calcd. For $C_{20}H_{23}NO_2^+$: 309.1731, found: 309.1729.



Benzyl 2',3'-dihydrospiro[cyclobutane-1,4'-cyclopenta[c]pyridine]-3'-carboxylate


The title compound was prepared according to the general procedure as described above in 81% yield. 1H NMR ($CDCl_3$, TMS, 300 MHz) δ 7.35 (m, 5H), 7.22 (d, $J = 6.0$ Hz, 1H), 6.30-6.23 (m, 3H), 5.49 (br, 1H), 5.23 (dd, $J_1 = 12.0$ Hz, $J_2 = 16.8$ Hz, 2H), 4.14 (s, 1H), 2.58-2.51 (m,

1H), 2.35-2.21 (m, 2H), 2.06-2.02 (m, 1H), 1.74-1.68 (m, 1H), 1.03 (t, $J = 7.2$ Hz, 1H); ^{13}C NMR (CDCl_3 , TMS, 75 MHz) δ 170.8, 140.2, 135.0, 133.6, 128.5, 128.4, 128.3, 124.3, 118.1, 116.7, 114.9, 67.4, 64.2, 42.4, 31.9, 29.9, 15.2.




Benzyl 2,3-dihydrospiro[cyclopenta[c]pyridine-4,1'-cyclopentane]-3-carboxylate

The title compound was prepared according to the general procedure as described above in 86% yield. ^1H NMR (CDCl_3 , TMS, 300 MHz) δ 7.38-7.34 (m, 5H), 7.25-7.23 (m, 1H), 6.25 (m, 2H), 5.97 (s, 1H), 5.69 (br, 1H), 5.25-5.22 (m, 2H), 4.27 (s, 1H), 2.28-2.25 (m, 1H), 2.02-2.00 (m, 1H), 1.67-1.45 (m, 6H); ^{13}C NMR (CDCl_3 , TMS, 75 MHz) δ 171.9, 139.6, 135.8, 134.8, 133.7, 128.4, 123.8, 117.9, 116.4, 115.5, 88.2, 67.4, 64.3, 47.9, 36.5, 34.9, 25.2.




Benzyl 2',3'-dihydrospiro[cyclohexane-1,4'-cyclopenta[c]pyridine]-3'-carboxylate

The title compound was prepared according to the general procedure as described above in 78% yield. ^1H NMR (CDCl_3 , TMS, 300 MHz) δ 7.38-7.25 (m, 5H), 7.15-7.13 (m, 1H), 6.25 (m, 2H), 6.17 (s, 1H), 5.31 (br, 1H), 5.14 (dd, $J_1 = 12.6$ Hz, $J_2 = 14.7$ Hz, 2H), 4.20-4.19 (m, 1H), 1.94-1.40 (m, 10H); ^{13}C NMR (CDCl_3 , TMS, 75 MHz) δ 170.7, 139.2, 135.1, 133.3, 128.4, 128.2, 128.1, 123.4, 118.4, 117.2, 116.5, 66.7, 62.1, 39.5, 36.4, 31.4, 25.7, 22.5, 21.8; HRMS Calcd. For $\text{C}_{21}\text{H}_{23}\text{NO}_2^+$: 321.1739, found: 321.1729.




Benzyl 2,2',3,3',5',6'-hexahydrospiro[cyclopenta[c]pyridine-4,4'-pyran]-3-carboxylate

The title compound was prepared according to the general procedure as described above in 67% yield. ^1H NMR (CDCl_3 , TMS, 300 MHz) δ 7.35-7.26 (m, 5H), 7.18 (d, J = 5.7 Hz, 1H), 6.28-6.27 (m, 3H), 5.45 (br, 1H), 5.22 (d, J = 6.3 Hz, 1H), 5.12 (d, J = 6.3 Hz, 1H), 4.17-4.16 (m, 1H), 3.88-3.74 (m, 4H), 2.12-2.08 (m, 1H), 1.83-1.66 (m, 3H); ^{13}C NMR (CDCl_3 , TMS, 75 MHz) δ 169.9, 139.3, 128.5, 128.1, 123.6, 118.7, 117.0, 67.1, 64.3, 64.1, 46.0, 37.5, 35.4, 31.6; HRMS Calcd. For $\text{C}_{20}\text{H}_{21}\text{NO}_3^+$: 323.1528, found: 323.1525.



Benzyl 1'-benzyl-2,3-dihydrospiro[cyclopenta[c]pyridine-4,4'-piperidine]-3-carboxylate


The title compound was prepared according to the general procedure as described above in 75% yield. ^1H NMR (CDCl_3 , TMS, 300 MHz) δ 7.39-7.26 (m, 10H), 7.15 (d, J = 5.1 Hz, 1H), 6.25-6.20 (m, 3H), 5.35 (br, 1H), 5.14 (dd, J_1 = 12.3 Hz, J_2 = 24.3 Hz, 2H), 4.18-4.17 (m, 1H), 3.53 (m, 2H), 2.55-2.52 (m, 4H), 2.08-1.98 (m, 2H), 1.77-1.72 (m, 2H); ^{13}C NMR (CDCl_3 , TMS, 75 MHz) δ 170.3, 139.0, 133.9, 133.7, 129.5, 129.2, 128.7, 128.54, 128.49, 128.2, 128.1, 128.0, 126.9, 123.7, 116.9, 66.9, 63.2, 50.0, 49.7, 37.9, 35.4, 31.2; HRMS Calcd. For $\text{C}_{27}\text{H}_{28}\text{N}_2\text{O}_2^+$: 412.2151, found: 412.2155.



Benzyl 2',3'-dihydrospiro[cycloheptane-1,4'-cyclopenta[c]pyridine]-3'-carboxylate


The title compound was prepared according to the general procedure as described above in 77% yield. ^1H NMR (CDCl_3 , TMS, 300 MHz) δ 7.37 (m, 5H), 7.19 (d, J = 6.0 Hz, 1H), 6.26-6.25 (m, 2H), 6.14 (m, 1H), 5.60 (br, 1H), 5.30 (d, J = 12.3 Hz, 1H), 5.15 (d, J = 12.3 Hz, 1H), 4.17 (s, 1H), 2.23-2.20 (m, 1H), 2.06-1.98 (m, 1H), 1.66-1.26 (m, 10H); ^{13}C NMR (CDCl_3 , TMS, 75 MHz) δ 171.0, 155.6, 138.9, 135.3, 131.9, 128.6, 123.7, 118.3, 117.2, 116.8, 67.4, 67.0,

44.4, 37.8, 32.3, 31.9, 24.8, 22.9.




Methyl 3,4,4-trimethyl-3,4-dihydro-2H-cyclopenta[c]pyridine-3-carboxylate

The title compound was prepared according to the general procedure as described above in 81% yield. ¹H NMR (CDCl₃, TMS, 300 MHz) δ 7.13 (d, *J* = 6.3 Hz, 1H), 6.24 (m, 2H), 6.07 (s, 1H), 5.94 (br, 1H), 3.84 (s, 3H), 1.51 (m, 6H), 1.09 (s, 3H); ¹³C NMR (CDCl₃, TMS, 75 MHz) δ 174.4, 137.6, 134.5, 123.5, 116.4, 116.0, 155.8, 67.5, 52.6, 39.3, 26.8, 21.7, 19.1; HRMS Calcd. For C₁₃H₁₇NO₂⁺: 219.1259, found: 219.1255.



Methyl 4,4-dimethyl-3-propyl-3,4-dihydro-2H-cyclopenta[c]pyridine-3-carboxylate


The title compound was prepared according to the general procedure as described above in 73% yield. ¹H NMR (CDCl₃, TMS, 300 MHz) δ 7.12 (d, *J* = 5.7 Hz, 1H), 6.23 (m, 2H), 6.04 (s, 1H), 5.98 (br, 1H), 3.84 (s, 3H), 2.13-2.12 (m, 1H), 1.88-1.78 (m, 1H), 1.51 (m, 3H), 1.28-1.21 (m, 1H), 1.07 (s, 3H), 0.84 (t, *J* = 6.9 Hz, 3H); ¹³C NMR (CDCl₃, TMS, 75 MHz) δ 173.8, 137.2, 135.0, 128.7, 123.4, 116.0, 155.5, 71.2, 52.5, 39.6, 31.8, 27.3, 18.2, 13.9.



Methyl 3-benzyl-4,4-dimethyl-3,4-dihydro-2H-cyclopenta[c]pyridine-3-carboxylate


The title compound was prepared according to the general procedure as described above in 72% yield. ¹H NMR (CDCl₃, TMS, 300 MHz) δ 7.32-7.23 (m, 2H), 7.13 (d, *J* = 6.0 Hz, 1H), 6.96-6.94 (m, 2H), 6.30 (m, 2H), 6.12 (s, 1H), 5.49-5.47 (m, 1H), 3.82 (s, 3H), 3.37 (d, *J* = 13.2 Hz, 1H), 3.22 (d, *J* = 13.2 Hz, 1H), 1.65 (m, 3H), 1.11 (s, 3H); ¹³C NMR (CDCl₃, TMS, 75 MHz) δ 172.5, 137.1, 136.4, 129.7, 128.2, 126.6, 123.7, 117.2, 116.3, 116.2, 72.1, 52.3, 40.1, 34.9,

27.3, 21.4.




Benzyl 4-phenyl-3,4-dihydro-2H-cyclopenta[c]pyridine-3-carboxylate

The title compound was prepared according to the general procedure as described above in 32% yield. ^1H NMR (CDCl_3 , TMS, 300 MHz) δ 7.35-7.18 (m, 8H), 7.08-7.07 (m, 2H), 6.37-6.35 (m, 1H), 6.31-6.29 (m, 1H), 5.81 (s, 1H), 5.46 (br, 1H), 5.06 (dd, $J_1 = 12.3$ Hz, $J_2 = 22.5$ Hz, 2H), 4.57 (d, $J = 7.8$ Hz, 1H), 4.30 (d, $J = 7.8$ Hz, 1H); ^{13}C NMR (CDCl_3 , TMS, 75 MHz) δ 170.9, 140.9, 140.5, 134.8, 128.4, 128.3, 128.1, 128.0, 126.8, 125.9, 124.8, 119.9, 117.0, 67.4, 62.4, 44.7; For $\text{C}_{22}\text{H}_{19}\text{NO}_2^+$: 329.1423, found: 329.1420.




Benzyl 4-phenyl-3,4-dihydro-2H-cyclopenta[c]pyridine-3-carboxylate

The title compound was prepared according to the general procedure as described above in 32% yield. ^1H NMR (CDCl_3 , TMS, 300 MHz) δ 7.46-7.26 (m, 5H), 7.13-7.11 (m, 3H), 6.93-6.92 (m, 2H), 6.38-6.37 (m, 1H), 6.31 (m, 1H), 5.97 (s, 1H), 5.81 (br, 1H), 5.08 (dd, $J_1 = 12.0$ Hz, $J_2 = 17.1$ Hz, 2H), 4.71 (d, $J = 5.4$ Hz, 1H), 4.55 (d, $J = 5.4$ Hz, 1H); ^{13}C NMR (CDCl_3 , TMS, 75 MHz) δ 169.6, 140.2, 139.5, 134.5, 132.0, 128.8, 128.7, 128.2, 127.9, 127.0, 126.8, 125.1, 120.2, 118.5, 116.4, 67.5, 60.6, 43.5; HRMS Calcd. For $\text{C}_{22}\text{H}_{19}\text{NO}_2^+$: 329.1416, found: 329.1413.




Benzyl 4-(4-methoxyphenyl)-3,4-dihydro-2H-cyclopenta[c]pyridine-3-carboxylate

The title compound was prepared according to the general procedure as described above in 35% yield. ^1H NMR (CDCl_3 , TMS, 300 MHz) δ 7.34-7.29 (m, 4H), 7.13-7.08 (m, 3H), 6.80 (d, J = 8.4 Hz, 2H), 6.36-6.35 (m, 1H), 6.31-6.29 (m, 1H), 5.80 (s, 1H), 5.51 (br, 1H), 5.05 (dd, J_1 = 12.3 Hz, J_2 = 15.0 Hz, 2H), 4.50 (d, J = 8.1 Hz, 1H), 4.26 (d, J = 8.1 Hz, 1H), 3.78 (s, 3H); ^{13}C NMR (CDCl_3 , TMS, 75 MHz) δ 171.0, 158.4, 140.4, 134.8, 133.7, 129.2, 128.4, 128.3, 128.0, 126.5, 124.8, 120.1, 119.8, 117.0, 113.7, 67.3, 62.8, 55.1, 44.2; HRMS Calcd. For $\text{C}_{23}\text{H}_{21}\text{NO}_3$ $^+$: 359.1521, found: 359.1522.




Benzyl 4-(4-methoxyphenyl)-3,4-dihydro-2H-cyclopenta[c]pyridine-3-carboxylate

The title compound was prepared according to the general procedure as described above in 35% yield. ^1H NMR (CDCl_3 , TMS, 300 MHz) δ 7.40-7.30 (m, 5H), 6.82 (d, J = 8.7 Hz, 2H), 6.62 (d, J = 8.7 Hz, 2H), 6.36-6.35 (m, 1H), 6.31-6.28 (m, 1H), 5.95 (s, 1H), 5.86-5.84 (m, 1H), 5.09 (dd, J_1 = 12.3 Hz, J_2 = 13.8 Hz, 2H), 4.66 (d, J = 5.1 Hz, 1H), 4.51 (d, J = 5.1 Hz, 1H), 3.71 (s, 3H); ^{13}C NMR (CDCl_3 , TMS, 75 MHz) δ 169.7, 158.2, 140.1, 134.6, 131.7, 128.9, 128.8, 128.7, 128.5, 127.4, 125.1, 120.1, 118.2, 116.3, 113.5, 67.5, 60.7, 55.0, 42.7; HRMS Calcd. For $\text{C}_{23}\text{H}_{21}\text{NO}_3$ $^+$: 359.1521, found: 359.1516.




Benzyl 4-(4-chlorophenyl)-3,4-dihydro-2H-cyclopenta[c]pyridine-3-carboxylate

The title compound was prepared according to the general procedure as described above in 40% yield. ^1H NMR (CDCl_3 , TMS, 300 MHz) δ 7.36-7.31 (m, 3H), 7.21 (d, $J = 8.4$ Hz, 2H), 7.13 (d, $J = 8.4$ Hz, 2H), 7.06 (m, 2H), 6.37-6.35 (m, 1H), 6.30-6.26 (m, 1H), 5.76 (s, 1H), 5.54 (br, 1H), 5.05 (m, 2H), 4.49 (d, $J = 8.4$ Hz, 1H), 4.27 (d, $J = 8.4$ Hz, 1H); ^{13}C NMR (CDCl_3 , TMS, 75 MHz) δ 170.6, 140.4, 140.2, 134.5, 132.6, 129.6, 128.5, 128.1, 125.8, 124.9, 120.1, 117.2, 67.6, 62.3, 44.4; HRMS Calcd. For $\text{C}_{22}\text{H}_{18}\text{ClNO}_2^+$: 363.1026, found: 363.1029.




Benzyl 4-(4-chlorophenyl)-3,4-dihydro-2H-cyclopenta[c]pyridine-3-carboxylate

The title compound was prepared according to the general procedure as described above in 40% yield. ^1H NMR (CDCl_3 , TMS, 300 MHz) δ 7.45-7.26 (m, 5H), 7.03 (d, $J = 8.4$ Hz, 2H), 6.82 (d, $J = 8.4$ Hz, 2H), 6.38-6.36 (m, 1H), 6.31-6.30 (m, 1H), 5.95 (s, 1H), 5.83 (br, 1H), 5.10 (dd, $J_1 = 12.0$ Hz, $J_2 = 16.2$ Hz, 2H), 4.69 (d, $J = 5.1$ Hz, 1H), 4.51 (d, $J = 5.1$ Hz, 1H); ^{13}C NMR (CDCl_3 , TMS, 75 MHz) δ 169.3, 140.1, 138.0, 134.3, 133.5, 132.4, 129.2, 128.9, 128.7, 128.3, 126.5, 125.2, 120.0, 118.7, 116.7, 67.7, 60.3, 42.7; HRMS Calcd. For $\text{C}_{22}\text{H}_{18}\text{ClNO}_2^+$: 363.1026, found: 363.1027.



Methyl 4-(4-methoxyphenyl)-3,4-dihydro-2H-cyclopenta[c]pyridine-3-carboxylate


The title compound was prepared according to the general procedure as described above in 35% yield. ¹H NMR (CDCl₃, TMS, 300 MHz) δ 7.34 (d, *J* = 6.0 Hz, 1H), 7.12 (d, *J* = 8.1 Hz, 2H), 6.83 (d, *J* = 9.0 Hz, 2H), 6.35-6.31 (m, 1H), 6.30-6.29 (m, 1H), 5.84 (s, 1H), 5.47-5.46 (br, 1H), 4.52 (d, *J* = 5.1 Hz, 1H), 4.20-4.17 (m, 1H), 3.78 (s, 3H), 3.64 (s, 3H); ¹³C NMR (CDCl₃, TMS, 75 MHz) δ 171.5, 158.4, 140.5, 134.1, 129.0, 126.1, 124.7, 119.9, 119.6, 116.9, 113.6, 62.6, 55.1, 52.6, 43.8.



Methyl 4-(4-methoxyphenyl)-3,4-dihydro-2H-cyclopenta[c]pyridine-3-carboxylate

The title compound was prepared according to the general procedure as described above in 35% yield. ¹H NMR (CDCl₃, TMS, 300 MHz) δ 7.42 (d, *J* = 6.0 Hz, 1H), 6.88 (d, *J* = 9.0 Hz, 2H), 6.71 (d, *J* = 8.7 Hz, 2H), 6.38-6.33 (m, 1H), 6.32-6.31 (m, 1H), 5.99 (s, 1H), 5.82-5.80 (m, 1H), 4.64 (d, *J* = 5.1 Hz, 1H), 4.52 (d, *J* = 5.4 Hz, 1H), 3.72 (m, 6H); ¹³C NMR (CDCl₃, TMS, 75 MHz) δ 170.3, 158.3, 140.3, 131.8, 128.8, 127.2, 125.0, 120.1, 118.1, 116.2, 113.5, 60.7, 55.0, 52.3, 42.7.

III. Preliminary Results for Catalytic asymmetric [6 + 3] Cycloaddition/Isomer-ization of Isocyanoacetate **1a** with Fulvene **2a**






Under argon atmosphere, AgOAc (3.3 mg, 0.02 mmol) and TF-Biphamphos (14.1 mg, 0.022 mmol) and were dissolved in 2 mL DCM, and stirred at room temperature for about 30min. Isocyanoacetate **2a** (0.2 mmol), Et₃N (0.03 mmol) were added sequentially. Then, the mixture was dropped to 0 °C and fulvene **1a** (0.3 mmol) was added. Once starting material was consumed (monitored by TLC), then the organic solvent was removed and the residue was purified by column chromatography to afford the product **3a** in 71% yield. The product was analyzed by HPLC to determine the enantiomeric excess: 28% ee (Chiralpak AS-H, *i*-propanol/hexane = 10/90, flow rate 1.0 mL/min, λ = 220 nm); t_r = 8.59 and 10.61 min.


V. References

- 1 (a) Stone, K. J.; Little, R. D. *J. Org. Chem.* **1984**, 49, 1849. (b) Erden, I.; Xu, F.-P.; Sadoun, A.; Smith, W.; Sheff, G.; Ossun, M. *J. Org. Chem.* **1995**, 60, 813. (c) Bandar, J. S.; Coscia, R. W.; Lambert, T. H. *Tetrahedron* **2011**, 67, 4364.
2. (a) Galan, B. R.; Kalbarczyk, K. P.; Szczepankiewicz, S.; Keister, J. B.; Diver, S. T. *Org. Lett.* **2007**, 9, 1203. (b) Elders, N.; Schmitz, R. F.; de Kanter, F. J. J.; Ruijter, E.; Groen, M. B.; Orru, R. V. A. *J. Org. Chem.* **2007**, 72, 6135.
3. Wang, C.-J.; Liang, G.; Xue, Z.-Y.; Gao, F. *J. Am. Chem. Soc.* **2008**, 130, 17250.


IV. ^1H NMR and ^{13}C NMR Spectra










(3b)










(3c)










(3d)













(3e)
























(3h)













































































(4d)








(5d)




C13-H27-12-22-1

Solvent: CDCl₃
Nucleon: 125 MHz
Mercury-300B "mercury300"
Relax. delay 1.000 sec
Pulse: 28.0 degrees
Acq. time: 0.500 sec
NUC1: 13C, 125.000 MHz
224 repetitions
OBSERVE: C13, 75.452851 MHz
DECOUPLE: H1, 300.0815297 MHz
P1: 0.120000 sec
on during acquisition
off during delay
WALTZ-16 modulated
D1: 1.000000 sec
Time: 0.000000 sec
Time: 0.000000 sec
FT size 32768
Total time 4 hr, 48 min, 8 sec




V. HPLC Chromatograms



(3a)

Data File D:\LC\DATA\H2L\H2L-8-79\H2L-8-79-2 2013-04-13 09-39-20\002-0101.D
Sample Name: H2L-8-79

```
=====
Acq. Operator   : TMC                      Seq. Line :    1
Acq. Instrument : Instrument 1              Location  : Vial 2
Injection Date  : 4/14/2013 12:40:16 AM     Inj       :    1
                                           Inj Volume: 5 µl
Acq. Method     : D:\LC\DATA\H2L\H2L-8-79\H2L-8-79-2 2013-04-13 09-39-20\ASH-10-90-10ML-
                  220NM.M
Last changed    : 1/14/2012 6:45:00 AM by H2L
Analysis Method : D:\LC\DATA\H2L\H2L-8-79\H2L-8-79-2 2013-04-13 09-39-20\002-0101.D\A.M (
                  ASH-10-90-10ML-220NM.M)
Last changed    : 10/21/2014 4:32:38 PM by HR
                  (modified after loading)
=====
```



Area Percent Report

```
=====
Sorted By      : Signal
Multiplier     : 1.0000
Dilution       : 1.0000
Use Multiplier & Dilution Factor with ISTDs
=====
```


Signal 1: VMD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU	Height [mAU]	Area %
1	8.600	VB	0.2919	2939.99219	148.67641	49.6720
2	10.613	BV	0.3099	2978.82544	138.08510	50.3280

Totals : 5918.81763 286.76151

Data File D:\LC\DATA\H2L\H2L-8-80\H2L-8-80A 2013-04-13 15-55-44\041-0101.D
Sample Name: H2L-8-80A

```
=====
Acq. Operator   : TMC                      Seq. Line :    1
Acq. Instrument : Instrument 1              Location  : Vial 41
Injection Date  : 4/14/2013 6:57:01 AM      Inj       :    1
                                           Inj Volume: 5 µl
Acq. Method     : D:\LC\DATA\H2L\H2L-8-80\H2L-8-80A 2013-04-13 15-55-44\ASH-10-90-10ML-
220NM-15MIN.M
Last changed    : 8/6/2012 2:28:33 AM by THL
Analysis Method : D:\LC\DATA\H2L\H2L-8-80\H2L-8-80A 2013-04-13 15-55-44\041-0101.D\DA.M (
ASH-10-90-10ML-220NM-15MIN.M)
Last changed    : 10/23/2014 5:07:14 PM by HR
(modified after loading)
=====
```



=====
Area Percent Report
=====

```
Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Use Multiplier & Dilution Factor with ISTDs
```

Signal 1: WVD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU	Height [mAU]	Area %
1	8.591	VB	0.2906	1859.17334	94.54090	36.1726
2	10.605	BB	0.3029	3280.55444	155.51765	63.8274

Totals : 5139.72778 250.05856

Instrument 1 10/23/2014 5:07:26 PM HR

Page 1 of 1